Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg in obesity and knee osteoarthritis
NCT05064735Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05064735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064735.